Belite Bio (NASDAQ:BLTE) CFO Hao-Yuan Chuang Sells 367 Shares of Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CFO Hao-Yuan Chuang sold 367 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total value of $66,188.45. Following the sale, the chief financial officer directly owned 93,433 shares of the company’s stock, valued at $16,850,641.55. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Belite Bio Stock Performance

NASDAQ BLTE opened at $166.26 on Friday. The company has a 50-day simple moving average of $152.11 and a 200 day simple moving average of $159.84. Belite Bio, Inc. Sponsored ADR has a 52-week low of $60.00 and a 52-week high of $200.00. The company has a market capitalization of $6.66 billion, a PE ratio of -65.72 and a beta of -1.22.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. As a group, analysts forecast that Belite Bio, Inc. Sponsored ADR will post -3.17 EPS for the current fiscal year.

Key Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: The FDA granted priority review to Belite Bio’s tinlarebant New Drug Application for Stargardt disease. The accelerated review sets an expected decision date in February 2027 and follows positive Phase 3 data, potentially shortening the path to commercialization for the company’s lead program. BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
• Positive Sentiment: HC Wainwright raised its price target to $214 from $200 and maintained a Buy rating, signaling continued analyst confidence in tinlarebant’s commercial potential. Belite Bio Price Target Increase
• Positive Sentiment: Second-quarter results exceeded expectations: Belite Bio reported a loss of $0.54 per share versus the consensus estimate of a $0.73 loss. The earnings beat may support sentiment, while management’s corporate update and earnings call provided additional detail on the company’s development programs. Belite Bio Second Quarter 2026 Results
• Neutral Sentiment: Belite Bio remains a clinical-stage biotechnology company, so its valuation and stock performance remain highly dependent on regulatory decisions, clinical execution and the future launch of tinlarebant. Belite Bio Q2 2026 Earnings Call Transcript
• Negative Sentiment: The company continues to report net losses, and analysts expect a full-year loss. With shares trading near their yearly high and at a loss-based price-to-earnings valuation, investors may be taking profits despite the positive FDA and earnings developments.

Institutional Investors Weigh In On Belite Bio

Several institutional investors and hedge funds have recently made changes to their positions in BLTE. Darwin Global Management Ltd. bought a new stake in Belite Bio in the 4th quarter worth about $486,915,000. RA Capital Management L.P. purchased a new stake in shares of Belite Bio during the 3rd quarter valued at about $64,750,000. Millennium Management LLC boosted its holdings in shares of Belite Bio by 2,594.6% during the 4th quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock valued at $89,399,000 after acquiring an additional 538,141 shares during the last quarter. RTW Investments LP grew its stake in shares of Belite Bio by 128.9% in the fourth quarter. RTW Investments LP now owns 715,332 shares of the company’s stock worth $114,425,000 after acquiring an additional 402,832 shares during the period. Finally, Perceptive Advisors LLC raised its holdings in shares of Belite Bio by 732.0% during the fourth quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock valued at $66,262,000 after purchasing an additional 364,451 shares during the last quarter. Institutional investors own 0.53% of the company’s stock.

Wall Street Analysts Forecast Growth

BLTE has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a report on Monday, July 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Belite Bio in a report on Wednesday. Truist Financial set a $217.00 price target on Belite Bio in a research note on Friday, May 22nd. Benchmark restated a “buy” rating on shares of Belite Bio in a report on Friday, May 22nd. Finally, HC Wainwright raised their target price on shares of Belite Bio from $200.00 to $214.00 and gave the stock a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $204.40.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.